Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

Infection

Volumn 42, Issue 1, 2014, Pages 37-42

  Kalin, G ^a   Alp, E ^a   Akin, A ^a   Coskun, R ^a   Doganay, M ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Acinetobacter spp.; Colistin; Multidrug resistance; Nephrotoxicity; Sulbactam; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE; B LAKTAM; COLISTIMETHATE; GLYCOPEPTIDE; NEOMYCIN; SULBACTAM; UNCLASSIFIED DRUG;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SKIN MANIFESTATION; SURVIVAL; TOXIC HEPATITIS; TRACHEAL ASPIRATION PROCEDURE; TRACHEOBRONCHIAL TOILET; TREATMENT RESPONSE; VENTILATOR; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898538991     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0495-y     Document Type: Article

References (27)

1. Alp E, Voss A. Ventilator associated pneumonia and infection control. Ann Clin Microbiol Antimicrob. 2006;5:7.
2. Alp E, Kiran B, Altun D, Kalin G, Coskun R, Sungur M, et al. Changing pattern of antibiotic susceptibility in intensive care units: ten years experience of a university hospital. Anaerobe. 2011;17:422-5.
3. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment. J Infect Chemother. 2012;18:872-7.
4. Alp E, Kalin G, Coskun R, Sungur M, Guven M, Doganay M. Economic burden of ventilator-associated pneumonia in a developing country. J Hosp Infect. 2012;81:128-30.
5. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 2010;51:1238-44.
6. Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2008;32:281-4.
7. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii . J Antimicrob Chemother. 2007;60:317-22. (Pubitemid 47243880)
8. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-8. (Pubitemid 36549630)
9. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8:751-62.
10. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high dose ampicillin-sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii. Ventilator associated pneumonia. J Infect. 2008;56:432-6.
11. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1998;42:793-802. (Pubitemid 29008082)
12. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25:343-8.
13. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS. International sepsis definitions conference. Crit Care Med. 2003;31:1250-6. (Pubitemid 36444440)
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 11th informational supplement. M100-S11. Wayne: NCCLS; 2001.
16. Alp E, Esel D, Yildiz O, Voss A, Melchers W, Doganay M. Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. Scan J Infect Dis. 2006;38:335-40. (Pubitemid 43832398)
17. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2010;35:297-300.
18. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:1-266.
19. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724-8.
20. Rodríguez-Hernández MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jiménez-Mejías ME, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother. 2001;47:479-82.
21. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002;46:1946-52. (Pubitemid 34535219)
22. Pachón-Ibáñez ME, Docobo-Pérez F, Jiménez-Mejias ME, Ibáñez-Martínez J, García-Curiel A, Pichardo C, et al. Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains. Eur J Clin Microbiol Infect Dis. 2011;30:895-901.
23. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53:393-5.
24. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;39:180-1.
25. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
26. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54:4503-5.
27. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-6.